Dr. Smith is a distinguished leader in biopharmaceutical development with over two decades of experience driving innovation in oncology, gene therapy, and immunotherapy. Currently, she serves as the President of Triangle Therapeutics Consulting, LLC and holds a position on the Board of Directors at Lifordi Immunotherapeutics. Dr. Smith has held key leadership roles at SpringWorks Therapeutics, where she led the development and FDA approval of Ogsiveo®, the first GSI approved for desmoid tumors, and led the development of mirdametinib for neurofibromatosis.

Her career includes pivotal contributions at United Therapeutics Corporation, where she was instrumental in the approval of Unituxin®, the first immunotherapy for high-risk neuroblastoma in both the U.S. and Europe. Dr. Smith’s work has consistently focused on advancing treatments for rare and complex diseases, demonstrating her commitment to improving patient outcomes through innovative medical solutions.

She earned her PhD in Microbiology from the University of New Hampshire and has published extensively in leading medical journals.